GAMMA Investing LLC Has $54,000 Position in Hims & Hers Health, Inc. (NYSE:HIMS)

GAMMA Investing LLC boosted its stake in Hims & Hers Health, Inc. (NYSE:HIMS) by 2,173.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,251 shares of the company’s stock after acquiring an additional 2,152 shares during the period. GAMMA Investing LLC’s holdings in Hims & Hers Health were worth $54,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Quest Partners LLC boosted its holdings in Hims & Hers Health by 5,944.1% in the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after acquiring an additional 3,507 shares during the last quarter. CWM LLC boosted its holdings in Hims & Hers Health by 21.4% in the third quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after acquiring an additional 1,054 shares during the last quarter. Quarry LP boosted its holdings in Hims & Hers Health by 91.0% in the third quarter. Quarry LP now owns 6,113 shares of the company’s stock valued at $113,000 after acquiring an additional 2,913 shares during the last quarter. Amalgamated Bank boosted its holdings in Hims & Hers Health by 55.9% in the second quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after acquiring an additional 2,354 shares during the last quarter. Finally, Daiwa Securities Group Inc. bought a new stake in Hims & Hers Health in the second quarter valued at approximately $142,000. 63.52% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

HIMS has been the topic of several analyst reports. TD Cowen reiterated a “buy” rating and issued a $28.00 target price on shares of Hims & Hers Health in a report on Wednesday, November 20th. Canaccord Genuity Group upped their target price on Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a report on Monday, December 2nd. BTIG Research started coverage on Hims & Hers Health in a report on Tuesday, January 7th. They set a “buy” rating and a $35.00 price target on the stock. Morgan Stanley started coverage on Hims & Hers Health in a report on Tuesday, December 17th. They set an “overweight” rating and a $42.00 price target on the stock. Finally, Needham & Company LLC increased their price target on Hims & Hers Health from $28.00 to $31.00 and gave the stock a “buy” rating in a report on Monday, January 6th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $25.13.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, CEO Andrew Dudum sold 188,888 shares of the firm’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $20.88, for a total transaction of $3,943,981.44. Following the transaction, the chief executive officer now directly owns 67,015 shares in the company, valued at approximately $1,399,273.20. This trade represents a 73.81 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Oluyemi Okupe sold 142,886 shares of the firm’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $29.93, for a total value of $4,276,577.98. Following the transaction, the chief financial officer now owns 112,186 shares in the company, valued at approximately $3,357,726.98. This trade represents a 56.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,063,707 shares of company stock worth $28,696,798. Corporate insiders own 17.71% of the company’s stock.

Hims & Hers Health Trading Down 1.2 %

NYSE HIMS opened at $25.41 on Monday. The company has a fifty day simple moving average of $27.21 and a 200 day simple moving average of $21.64. Hims & Hers Health, Inc. has a 12-month low of $8.14 and a 12-month high of $35.02. The company has a market cap of $5.55 billion, a P/E ratio of 57.75 and a beta of 1.31.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. During the same quarter last year, the firm posted ($0.04) EPS. Hims & Hers Health’s revenue was up 77.1% compared to the same quarter last year. Sell-side analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.